Oncology/Hematology
Lymphoma
More in Lymphoma
Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate
Jun 16, 2023
SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease
Jun 04, 2023
Continuing Medical Education
1.00 CME Credits